参考文献

1.Travis WD，Brambilla E，Noguchi M，et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol，2011，6：244-285.

2.Warth A，Muley T，Meister M，et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stageindependent predictor of survival. J Clin Oncol，2012，30：1438-1446.

3.Hung JJ，Jeng WJ，Chou TY，et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg，2013，258：1079-1086.

4.Yoshizawa A，Motoi N，Riely GJ，et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma：prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol，2011，24：653-664.

5.Sica G，Yoshizawa A，Sima CS，et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol，2010，34：1155-1162.

6.Zhang Y，Wang R，Cai D，et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol，2014，9：1772-1778.

7.Xu S，Xi J，Jiang W，et al. Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma. Ann Thorac Surg，2015，99：961-967.

8.Tsao MS，Marguet S，Le Teuff G，et al. Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. J Clin Oncol，2015，33：3439-3446.

9.Wang R，Wang L，Li Y，et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res，2014，20：4107-4114.

10.Akbay EA，Koyama S，Carretero J，et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov，2013，3：1355-1363.

11.Tang Y，Fang W，Zhang Y，et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget，2015，6：14209-14219.

12.Zhou Q，Cheng Y，Yang JJ，et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR （CTONG0806）：a multicenter randomized trial. Ann Oncol，2014，25：2385-2391.

13.Zhou Q，Zhang XC，Chen ZH，et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol，2011，29：3316-3321.

14.Zhao N，Zhang XC，Yan HH，et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR：a meta-analysis of randomized controlled clinical trials. Lung Cancer，2014，85：66-73.

15.Lee JK，Hahn S，Kim DW，et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor：a metaanalysis. JAMA，2014，311：1430-1437.

16.Zhou C，Wu YL，Chen G，et al. Final overall survival results from a randomised，phase Ⅲ study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer（OPTIMAL，CTONG-0802）. Ann Oncol，2015，26：1877-1883.

17.Wu YL，Zhou C，Liam CK，et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer：analyses from the phase Ⅲ，randomized，open-label，ENSURE study. Ann Oncol，2015，26：1883-1889.

18.Zeng Z，Yan HH，Zhang XC，et al. Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer，2014，86：219-224.

19.Yang JC，Wu YL，Schuler M，et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma （LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised，phase 3 trials. Lancet Oncol，2015，16：141-151.

20.Yang JC，Sequist LV，Geater SL，et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations：a combined post-hoc analysis of LUX-Lung 2，LUX-Lung 3，and LUX-Lung 6. Lancet Oncol，2015，16：830-838.

21.Zhou C，Wu YL，Chen G，et al. BEYOND：A Randomized，Double-Blind，Placebo-Controlled，Multicenter，Phase Ⅲ Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol，2015，33：2197-2204.

22.Lu S，Li L，Luo Y，et al. A multicenter，open-label，randomized phase Ⅱ controlled study of rh-endostatin（Endostar） in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol，2015，10：206-211.

23.Liang W，Zhang L，Jiang G，et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol，2015，33：861-869.

24.Cao C，Zhu ZH，Yan TD，et al. Video-assisted thoracic surgery versus open thoracotomy for non-small-cell lung cancer：a propensity score analysis based on a multi-institutional registry. Eur J Cardiothorac Surg，2013，44：849-854.

25.Liu L，Mei J，Pu Q，et al. Thoracoscopic bronchovascular double sleeve lobectomy for non-small-cell lung cancer. Eur J Cardiothorac Surg，2014，46：493-495.

26.Zhang Y，Sun Y，Wang R，et al. Meta-analysis of lobectomy，segmentectomy，and wedge resection for stage I non-small cell lung cancer. J Surg Oncol，2015，111：334-340.

27.Rami-Porta R，Bolejack V，Crowley J，et al. The IASLC Lung Cancer Staging Project：Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol，2015，10：990-1003.

28.Hung MH，Hsu HH，Chen KC，et al. Nonintubated thoracoscopic anatomical segmentectomy for lung tumors.Ann Thorac Surg，2013，96：1209-1215.

29.Wang Z，Chen R，Wang S，et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One，2014，9：e110780.

30.Mok T，Wu YL，Lee JS，et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res，2015，21：3196-3203.

31.An SJ，Chen ZH，Su J，et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One，2012，7：e40109.

32.Wang Z，Shen Z，Li Z，et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proc Natl Acad Sci USA，2015，112：9990-9995.

33.Li F，Han X，Li F，et al. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response. Cancer Cell，2015，27：698-711.

34.Sanchez-Cespedes M，Parrella P，Esteller M，et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res，2002，62：3659-3662.

35.Chen Z，Cheng K，Walton Z，et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature，2012，483：613-617.

36.Ji H，Ramsey MR，Hayes DN，et al. LKB1 modulates lung cancer differentiation and metastasis. Nature，2007，448：807-810.

37.Mamon HJ，Yeap BY，Janne PA，et al. High risk of brain metastases in surgically staged ⅢA non-small-cell lung cancer patients treated with surgery，chemotherapy，and radiation. J Clin Oncol，2005，23：1530-1537.

38.Gore EM，Bae K，Wong SJ，et al. Phase Ⅲ comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer：primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol，2011，29：272-278.

39.Wang SY，Ye X，Ou W，et al. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer，2009，64：238-243.

40.Li N，Zeng ZF，Wang SY，et al. Randomized phase Ⅲ trial of prophylactic cranial irradiation versus observation in patients with fully resected stage ⅢA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy. Ann Oncol，2015，26：504-509.

41.Zhong W，Yang X，Yan H，et al. Phase Ⅱstudy of biomarker-guided neoadjuvant treatment strategy for ⅢA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol，2015，8：54.